Regulated information

Vétoquinol continues to launch reference products

Lure (France), December 16, 2013 – In line with its strategy of developing products targeting fast-growing markets, the Vétoquinol Group expands its Flexadin® range world-wide and launches Zylkène® in the United States.

2013 3rd quarter sales show organic growth

Vétoquinol generated sales of €74.0 million in the 3rd quarter of 2013, a drop of 0.1% based on reported data, and a 4.4% increase at constant exchange rates.

The reference products demonstrate solid growth

Lure (France), August 29, 2013 – At its meeting on August 27, 2013, the Vétoquinol S.A. Board of Directors reviewed the Group’s results, and approved the financial statements for the first six months of 2013.

Q2 2013 sales

Vétoquinol posted Q2 2013 sales of €70 million, up 0.3% on reported figures and up 1.4% like for like.

Vétoquinol : 80 years striving for animal health worldwide

Founded in 1933, Vétoquinol is now a leading global animal health company.
The number 10 global animal health company and the third
largest in France, the Vétoquinol Group combines sustainability,
growth and independence in an increasingly competitive world
market.
Committed to the protection and well-being of both animals
and people, Vétoquinol creates, develops and sells veterinary
drugs and non-medical products all over the world.
The company is widely reputed for its expertise in the fields of infectious diseases, pain and inflammation in livestock (cattle and pigs) and pets (dogs and cats).
For over 80 years, Vétoquinol's pursuit of growth has been underpinned by strong values of team spirit, performance and the sharing of corporate culture and know-how with customers, vets, breeders, partners and employees alike.

Financial statements 2012

1.1CONSOLIDATED FINANCIAL STATEMENTS p.4

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2012 (french version)

The registration document of Vétoquinol relative to fiscal year 2012, including the annual financial report relative to fiscal year 2012, was registered with the Autorité des marchés financiers (“the AMF”) on April 15th, 2013.

Q1 2013 sales

Lure, April 16, 2013 – Vétoquinol posted Q1 2013 sales of €75.5 million, compared to €77.0 million for the first quarter of 2012. Like-for-like sales amounted to €76.0 million, compared to €77.0 million in Q1 2012.

2012 ANNUAL RESULTS

SFAF Meeting March 27, 2013

2012, return to growth

Lure, March 26, 2013 – The Vétoquinol Board meeting of March 7, 2013 reviewed the Group's business and approved the 2012 financial statements.